Impact of prior treatment with immune checkpoint inhibitors on dacarbazine efficacy in metastatic melanoma-Reference-Cited by-同舟云学术

Impact of prior treatment with immune checkpoint inhibitors on dacarbazine efficacy in metastatic melanoma

Published:2021-07-14 Issue:7 Volume:125 Page:948-954
ISSN:0007-0920
Container-title:British Journal of Cancer
language:en
Short-container-title:Br J Cancer

Author:

Bouchereau Sarah,Chaplain Louise,Fort Magali,Beauchet Alain,Sidibé Thomas,Chapalain Marie,Gonzalez-Lara Leire,Longvert Christine,Blom Astrid,Saiag Philippe,Funck-Brentano Elisa^ORCID

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Link

https://www.nature.com/articles/s41416-021-01486-8.pdf

Reference37 articles.

1. Ugurel S, Röhmel J, Ascierto PA, Flaherty KT, Grob JJ, Hauschild A, et al. Survival of patients with advanced metastatic melanoma: the impact of novel therapies-update 2017. Eur J Cancer. 2017;83:247–57.

2. Robert C, Grob JJ, Stroyakovskiy D, Karaszewska B, Hauschild A, Levchenko E, et al. Five-year outcomes with dabrafenib plus trametinib in metastatic melanoma. N Engl J Med. 2019;381:626–36.

3. Ascierto PA, Dummer R, Gogas HJ, Flaherty KT, Arance A, Mandala M, et al. Update on tolerability and overall survival in COLUMBUS: landmark analysis of a randomised phase 3 trial of encorafenib plus binimetinib vs vemurafenib or encorafenib in patients with BRAF V600-mutant melanoma. Eur J Cancer. 2020;126:33–44.

4. Ribas A, Daud A, Pavlick AC, Gonzalez R, Lewis KD, Hamid O, et al. Extended 5-year follow-up results of a phase Ib study (BRIM7) of vemurafenib and cobimetinib in BRAF-mutant melanoma. Clin Cancer Res. 2020;26:46–53.

5. Hamid O, Robert C, Daud A, Hodi FS, Hwu WJ, Kefford R, et al. Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001. Ann Oncol. 2019;30:582–8.

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Therapeutic Treatment Options for In-Transit Metastases from Melanoma;Cancers;2024-09-03

2. The role of dacarbazine and temozolomide therapy after treatment with immune checkpoint inhibitors in malignant melanoma patients: A case series and meta‐analysis;Pigment Cell & Melanoma Research;2023-12-29

3. Chemotherapie nach Progress unter Immuncheckpoint-Inhibition beim metastasierten malignen Melanom: Fallbericht und Literaturübersicht;TumorDiagnostik & Therapie;2023-11

4. Chemotherapy in Cutaneous Melanoma: Is There Still a Role?;Current Oncology Reports;2023-03-29

5. Chemotherapie nach Progress unter Immuncheckpoint-Inhibition beim metastasierten malignen Melanom: Fallbericht und Literaturübersicht;Deutsche Zeitschrift für Onkologie;2023-03